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Abstract
Natural Killer (NK) cells are highly cytotoxic and specific towards certain types of
cancer cells and are therefore a potential target for immunotherapy. In order to determine
how NK cells acquire these traits, K562-mb15-41BBL cancer cells, specially modified
leukemia cells designed to enhance NK cells for cancer eradication, were tagged with an
Alexa Fluor 647 (A647) fluorescent dye and cultured with peripheral blood mononuclear
cells (PBMCs) over a week. Non labeled K562-mb15-41BBL cells were used as a control.
The co-incubation of PBMCs and K562s is intended to show which cells from the mixed
PBMC culture interact directly with the cancer cells by way of A647 dye transfer. K562s can
specify NK cells and increase cytotoxicity, but the using of whole K562 cell is inapplicable in
a clinical setting. To test a new strategy, plasma membrane (PM) particles made from the
K562-mb15-41BBL were labeled and cultured with PMBCs. Results were obtained by flow
cytometry, utilizing specific antibodies CD56, CD14, and CD3 to identify labeled NK cells,
natural killer-like T cells (NKT) and T cells. K562-mb15-41BBL cells labeled mostly (NKT)
cells, with little expression of the A647 on pure NK cells, while PMs labeled NK cells and T
cells at high rates, indicating that the first step of NK expansion involves direct contact with
K562 cells. Further studies should be aimed at distinguishing the two culturing methods, to
determine if the size of K562 cells inhibits the specification of NK cells and how to reduce T
cell interaction with the K562-mb15-41BBL cells to allow for higher amounts of NK
expansion. Determining how NK cells interact with K562-mb15-41BBL cells will allow for
faster expansions of NK cells in the future, leading to improved and better treatments when
this method of immunotherapy eventually moves to clinical trials.
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Introduction
Cancer affects every race, height, weight, sex, and aged person in the world and killed 8.2
million people worldwide in 2012 (Stewart 2014). Treatment of this disease would solve one of
the world’s most destructive sicknesses. The conventional methods for treating cancer consist of
chemotherapy, radiation, and surgical removal. Traditional chemotherapy targets the cancer cells
by preventing their mitosis, or cell division, in some manner- often by disrupting replication via
genetic mutation (Malhotra and Perry, 2003). Radiation is used to further mutate the cancer cells
beyond the point of reliable replication, causing their death. Surgery removes tumors from the
body to prevent the cancer from spreading to other parts of the body. It also reduces the number of
cancer cells that chemotherapy and radiation would have to target. These three treatments are
often used in conjunction with each other in order to maximize the benefits. The treatments are not
without their side effects, however. Chemotherapy is not specific to cancer cells; rather it targets
any rapidly dividing cells, which include healthy epithelial cells in the stomach lining, bone
marrow cells, hair follicles, and testes (Corrie, 2008; Malhotra and Perry, 2003). Radiation cannot
be localized to purely cancerous cells, and so healthy cells that reside around the cancer can
actually be turned cancerous (Schneider, 2011). Surgery can only remove large groups of
cancerous cells. If it were to miss a single cell, cancer could theoretically reemerge in the patient
from cancer stem cells. The existing forms of cancer treatment are, while advancing, clearly
flawed at their roots. A better method of treatment is needed, and it is currently being researched
through the treatment of the hallmarks of cancer.
First defined at the cellular level by Douglas Hanahan and Robert Weinberg (2000), the
hallmarks of cancer have ten characteristics: sustaining proliferative signaling, evading growth
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suppressors, avoiding immune destruction, enabling replicative immortality, tumor-promoting
inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and
mutation, resisting cell death, and deregulating cellular energetics (Hanahan and Weinberg 2011).
Although new therapies have emerged in the past decade to explicitly target the cellular hallmarks
of cancer, termed “the rational treatment of cancer”, some of these strategies are still in their
infancy (Hanahan and Weinberg, 2011). Immunotherapy, or the boosting of the body’s natural
immune system to fight cancer, and the method under investigation here, is a potential cure with
minimal side effects to the patient. In this study, the goal is to understand the cellular signaling
pathway of natural killer (NK) immune cells, with regards to the specific interaction between K562
cancer cells and the NK cells, resulting in expansion of the NK cells as part of a possible cancer
treatment plan.

Cells of The Immune System
The immune system is the body’s way of protecting itself from bacteria, viruses, parasites,
and rogue cells, such as cancer. It is split into two primary functioning parts: the adaptive immune
system and the innate immune system (Parkin and Cohen, 2001). Both seek to remove all of the
aforementioned threats; they merely go about it in different ways.
The adaptive immune system consists of two primary cell types: T lymphocytes and B
lymphocytes. T lymphocytes are distinguished from B lymphocytes in that they present a T-cell
receptor on their membranes, and the cells mature in the thymus. B lymphocytes, by contrast,
express B-cell receptors on their membranes and originate and mature in bone marrow. The
function of T lymphocytes is to induce cell apoptosis, but different types of T lymphocytes go
about the process in different ways (Parkin and Cohen, 2001). One type of T lymphocyte (CD8+ T
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lymphocyte) recognizes an antigen that is presented by an infected cell (Guermonprez et al., 2002;
Parkin and Cohen, 2001). This antigen is presented to the CD8+ T lymphocyte through a MHC
class I molecule located on the infected cell (Gao and Jakobsen, 2000; Guermonprez et al., 2002).
The T lymphocyte has a reciprocal receptor on its membrane, the CD8 receptor, and when it
recognizes the antigen, it causes the infected cell to initiate cell apoptosis via a molecule called
perforin (Parkin and Cohen, 2001). Other T lymphocytes, like CD4+ T lymphocytes, recognize
antigens presented via MHC class II molecules on infected cells. These infected cells are
phagocytized by macrophages and other innate immune system cells, broken down, and their
corresponding antigens are attached to MHC class II molecules. CD4+ T lymphocytes do not
directly initiate cell apoptosis, instead releasing cytokines like interleukin-2 (IL-2) and interferon-γ
(IFN-γ) which causes CD8+ cells, B lymphocytes and macrophages, respectively, to activate and
destroy harmful cells (Parkin and Cohen, 2001; Zhu et al., 2010).
B lymphocytes remove antigens from the blood, but rather than acting on the infected cells
themselves, the B lymphocytes target antigens while they reside in the bloodstream (Parkin and
Cohen, 2001). B lymphocytes use antibodies such as IgM, IgG, and IgA to overwhelm antigens in
the blood and do not induce apoptosis (Clark et al., 2004; Parkin and Cohen, 2001). They instead
bind to free-floating antigens or ones bound to MHC class II molecules in macrophages (Parkin
and Cohen, 2001). Once the B lymphocytes have found an antigen, they proliferate into short-term
plasmoblasts, which remove the immediate antigen problem by secreting large amounts of
antibodies to overwhelm the pathogen, and memory B lymphocytes, which remain in the body in
case of a secondary infection by the same pathogen (Parkin and Cohen, 2001). This process,
however, does not happen without the assistance of helper T lymphocytes, which stimulate the
further production of B lymphocytes via cytokines (Clark et al., 2004; Parkin and Cohen, 2001).
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The body’s first line of defense against invasive agents such as pathogens, worms, and
parasites is the innate immune system (Hato and Dagher, 2015). The first responding cells are
typically neutrophils, followed closely by macrophages and dendritic cells (Hato and Dagher,
2015; Parkin and Cohen, 2001). Upon finding a pathogen, the cells phagocytize it and release
cytokines that activate inflammation in the surrounding tissue (Hato and Dagher, 2015). These
cells are responsible for recruiting adaptive immune cells such as T lymphocytes and B
lymphocytes by producing MHC class II receptor molecules. After this initial response, other
innate immune cells are able to respond to the infection. These cells include additional neutrophils,
basophils, eosinophils, phagocytes, mast cells, and NK cells (Parkin and Cohen, 2001) .
Neutrophils, the most abundant phagocyte, kill invasive bacteria and other pathogens with the
granules contained within them. Similarly, basophils and eosinophils release reactive agents,
histamine and toxic proteins, respectively, to destroy the invasive pathogens (Jiang and Zhou,
2015). Mast cells also release histamine, although these cells primarily reside in mucosal
membranes and connective tissues, and are responsible for summoning neutrophils and
macrophages to the site of infection (Parkin and Cohen, 2001).

T Cell Immunotherapy
Modifying the immune system to create a therapy is considered a possible treatment for
cancer. Modifying T lymphocytes for cancer treatment is a field currently being explored by the
immunotherapy community (Jiang and Zhou, 2015; Simon et al., 2007; Singh et al., 2011). After
IL-2, an interleukin that signals growth of immune system lymphocytes, was discovered in the
supernatant of T lymphocytes in 1976 it has been used to help culture immune cells (Morgan et al.,
1976; Sim and Radvanyi, 2014). IL-2 was also used to boost the cytotoxicity of both T
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lymphocytes and NK cells in clinical trials (Welte et al., 1982). IL-2 is essential for the
development of T lymphocytes and activating T lymphocytes to induce cell death (Jiang and Zhou,
2015). It was then determined that if T lymphocytes were cytotoxic to cancerous cells, expanding
them with IL-2 would help treat cancer. Large amounts of IL-2 were used to treat patients with
metastatic melanoma, causing remission in 5-10% of patients and curing up to 70% of those
patients (Rosenberg 2012). If too much IL-2 is injected into patients, they can experience a fatal
side effect called capillary leak syndrome, creating a serious drawback to IL-2 immunotherapies
(Bachanova and Miller, 2014; Miller, 2015). IL-2 therapies were not as successful as intended,
especially with capillary leak syndrome as a potential side effect, leading to the use of T
lymphocytes in immunotherapy (Sim and Radvanyi, 2014).
The use of pure T lymphocytes in cancer immunotherapy is extensive. One such example
is in the field of tumor infiltrating lymphocytes (TILs). These TILs are isolated from the tumors of
the individual themselves and are specific for the tumor’s antigens. Over 50% of malignant
melanoma patients received a significant response when treated with autologous TILs. These TILs
are now able to be expanded, or allowed to selectively proliferate, ex vivo and have lead to clinical
trials for patients with extreme cases of malignant melanoma (Junker et al., 2012). The IL-2
problem remains, however, as large amounts of this cytokine are needed to keep the TILs in high
numbers (Miller, 2015; Sim and Radvanyi, 2014). Additionally, in order to expand the TILs
properly, surgery must be performed to obtain pieces of the tumor, making it a less than ideal
strategy for patients with tumors in difficult to reach places (Junker et al., 2012).
Another form of T lymphocyte immunotherapy is chimeric antigen receptor T lymphocyte
based therapy (CAR-T) (Bagg and June, 2011; Singh et al., 2011). These chimeric antigen
receptors, which are isolated from expanded T lymphocytes, combine a specific antibody domain
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with that of a CD3 chain (Bagg and June, 2011). With the inclusion of CD137, also known as 41BB, a signaling domain for tumor necrosis factor, CAR-Ts were able to persist in vivo, allowing
for better cancer cytotoxicity (Bagg and June, 2011). CAR-T cells are specifically needed because
in cancerous cells, MHC presenting molecules are often down regulated, creating a scenario in
which most immune system cells are unable to recognize the cancerous cells (Hanahan and
Weinberg, 2011). CAR-T cells, however, are able to recognize these cancerous cells with MHC
down-regulation (Jiang and Zhou, 2015). An issue arises, however, when choosing the target
receptor that the CAR-T must affect on the cell. Cancerous or not, many cells have the same
receptors; a good example lies in malignant and healthy B lymphocytes, which both express CD19
receptors (Bagg and June, 2011; Davila et al., 2014). The CAR-T cells in one study removed the
malignant cells well, but in subsequent months the patients could not regrow B lymphocytes, as the
CAR-T cells were still targeting them, healthy or not (Bagg and June, 2011). Thus, even
engineered T lymphocytes fail to safely and reliably treat cancer and need additional aides such as
surgery or IL-2 to continue proliferating in vivo, making them an unreliable treatment option in
their current state.

Natural Killer Cells in Immunotherapy
Due to the limited success of T lymphocyte immunotherapy, NK cells are currently being
considered as a model for cancer treatment. NK cells, which were originally considered part of the
innate immune system and are now considered both innate and adaptive, do not attack invasive
pathogens (Vivier et al., 2011). Rather, they attack infected or abnormally growing host cells,
inducing apoptosis in the target cell (Yoon et al., 2015). They will also attack cancerous cells,
providing a line of defense against harmful cells produced by the host (Vivier et al., 2012). This
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is done through the recognition of an abnormally low number of MHC class I molecules present
on the surface of the cell, a trait that normally is present only in cancerous cells (Shifrin et al.,
2014). The difference between these cells and those of the adaptive immune system is that the
NK cells do not require pre-activation. Rather, the NK cells are able react immediately to the
cancer, making them ideal in fighting it.
NK cells were originally classified as part of the innate immune system (Vivier et al.,
2011). This, generally speaking, would relegate them to a short-lived lifespan and prevent them
from adapting to various pathogens, as adaptation is what defines the adaptive immune system. In
recent years, however, it has been discovered that NK cells are capable of adapting and surviving
long-term (Min-Oo et al., 2013). These studies have specifically focused on virus-driven
pathogens, but the discovery of the memory-like NK cells leads to future questions about the
ability of NK cells to function in immunotherapy against cancer. A study has been conducted to
determine how NK cells preactivated with IL-12/15/18 affect tumors and cancer cells, and they
concluded that NK cells that are activated with IL-12/15/18 respond effectively against cancer, and
even interact with CD4+ T lymphocytes, the cells specifically used to activate and change other
adaptive cells. The NK cells in this study were injected into tumor-ridden mice, and when
combined with irradiation, reduced the growth of tumor size. Furthermore, the NKs gathered in
tumor tissue and persisted in high numbers, but only in the presence of CD4+ cells, due to the IL-2
produced by these cells. This IL-2 was also essential in the rapid expansion of the NK cells, which
was determined by the high levels of IL-2 receptor chains present on the IL-12/15/18 preactivated
NK cells (Ni et al., 2012).
NK cells have also been cultured with K562 cells, which are immortalized myelogenous
leukemia cells. The NK cells cultured with the K562 cells seem to retain a memory-like state
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when reintroduced to K562s (Romee et al., 2012). It stands to reason, then, that NK cells might be
an ideal cell type for use in cancer immunotherapy.
In order to use NK cells as an effective treatment for cancer, the number of cancer-seeking
NK cells present in the body must be increased. The expansion of NK cells functions similarly to
that of T lymphocytes, where low doses of IL-2 cause NK cell proliferation and expansion
(Bachanova and Miller, 2014; Sim and Radvanyi, 2014; Yoon et al., 2015). At high doses in vivo,
however, IL-2 proves to be quite hazardous, causing capillary leaking in many patients (Bachanova
and Miller, 2014). Additionally, IL-2 proliferates T lymphocytes as well as NK cells. These T
lymphocytes take up the IL-2 at rates much higher than NK cells, preventing pure IL-2
introduction from being a usable immunotherapy methodology (Simon et al., 2007). Another
immunotherapeutic method involves utilizing the body’s own NK cells and increasing their
cytotoxicity via antibody dependent cell-mediated cytotoxicity (ADCC). This method requires the
administration of activating cytokines such as IL-12, IL-2, and IL-21, as well as various antibodies
like disaloganglioside to alter the NK Fc receptor CD16 (Alderson and Sondel, 2011; Cheng et al.,
2013). This type of activation is effective, but only for tumor cells that utilize the ADCC effector
pathway and is therefore not useful in all patients.
A methodology must be created so that NK cells can be expanded outside the body without
expanding T lymphocytes, so as to minimize IL-2 usage as well as potential damage to the
recipient when reintroduced. Furthermore, this methodology must be relatively rapid in order to be
considered a proper treatment for cancer. Therefore, an ideal NK cancer immunotherapy involves
an artificial expansion of NK cells ex vivo and the reintroduction of said cells in vivo (Bachanova
and Miller, 2014). Pure transplants of ex vivo expanded, allogeneic NK cells into the patient was
effective, with positive results against renal cell carcinoma and Hodgkin’s disease, while
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simultaneously having few negative side effects (Cheng et al., 2013) When transplanted, 5 of 19
patients with poor-prognosis went into complete remission. These remissions were accompanied
by highly increased levels of IL-15, a chemokine, essential for NK expansion, suggesting that the
NK cells could expand in vivo (Miller et al., 2005). Unfortunately, the patient’s own immune
system rejects the unfamiliar NK cells over time (Vivier et al., 2012). It is possible to expand NK
cells in vivo that come from NK cell lines, such as NK-92 or NKL cell lines (Cheng et al., 2012).
The benefit of these cell lines is an increased cytotoxicity to many different types of cancers, due to
the large variety of receptors present on the NK cells. The process itself is considered safe enough
to have begun FDA approved testing on advanced malignant melanoma patients in the United
States (Cheng et al., 2012). This particular strategy, while effective, also suffers from immune
rejection, rendering it less effective. Therefore, auto-expansion, or the expansion of a person’s
own NK cells, is the only currently plausible method of NK immunotherapy. My thesis project
sought to resolve some of the problems of generating a NK culture with an individual’s own cells.

Culturing Natural Killer Cells
In order for NK cells to expand, they must be cultured with the proper growth factors, as
well as a high concentration of potential targets for the NKs, in this case K562 leukemia cells
(Cheng et al., 2012). The goal of the culture is to expand the NK cells without letting the cancer
cells expand out of control. For this reason, K562 cells are treated using mitomycin c, a DNA
cross-linking agent, which prevents the cells from proliferating (Bae and Lee, 2014). This
essentially makes the K562 cancer cells into a food source for the NK cells, which along with IL-2
creates ideal conditions for expansion (Figure 1). When cultured together along with IL-2, cell
expansion was significantly increased. Unfortunately, the expansion of cells includes T
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lymphocytes, which does not solve the issue of pure NK cell expansion. This culture, however,
also increased cytotoxicity against many different types of cancer cell lines, like Jurkat, a T
lymphocyte leukemia line, and MCF-7, a human breast cancer cell line (Bae and Lee, 2014). This
shows that the theory of expansion is correct, but the method of doing so is imperfect.
A method had to be developed to avoid the T lymphocyte expansion issue without
excessive IL-2 addition. A procedure was developed that would allow NK cells to come into
contact with the surface receptors required for expansion, while keeping T lymphocyte levels
within a reasonable limit. This process involved creating a K562 cell line that expresses membrane
bound IL-15 and 4-1BBL known also as CD137, on its surface (Oyer et al., 2015). IL-15 is a
cytokine that activates NK cells and specifies them for cancer destruction (Ni et al., 2012). 41BBL is a trans-membrane cytokine that interacts with T lymphocytes, specifically CD8+
lymphocytes (Mittler et al., 2004). These membrane-bound proteins allow for activation of the NK
cells to seek and destroy the cancer cells. Expansion using these engineered K562 cells, called
K562-mb15-41BBL cells, creates a 277-fold expansion over three weeks and keeps T lymphocyte
counts between 5% and 65% (Oyer et al., 2015). Therefore, the added membrane-bound receptors
do not negatively influence the NK cells proliferation or function and can be used for expansion of
NK cells without fear of a negative impact.
This method remains flawed, however, for use beyond the purely experimental. There is
no conventional way to sort peripheral blood mononuclear cells (PBMCs), the source from which
NK cells are proliferated, out from a culture. Furthermore, injection of the whole culture would
result in placing new cancer cells (K562s) into the patient’s body- a less than advisable practice.
The cancer cells have been treated with the mitomycin c, but the chance of injecting even one
living cancer cell is too high. A novel method was created to culture the NK cells without the
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threat of transmitting cancer- the creation of plasma-membrane particles from K562-mb15-41BBL
cancer cells (Oyer et al., 2015). The K562-mb15-41BBL cells have IL-15 and ligand 41BB bound
to the membrane, creating focus points for the NK cells to target. Creating the K562-mb15-41BBL
cancer cells and then lysing them in a nitrogen cavitation vessel synthesizes the particles. The
particles contain all the membrane bound cytokines the original cancer cells had, but now are
destroyed, preventing them from potentially proliferating inside a patient. The plasma membrane
particles not only help NK cells proliferate, but they also cause all other types of PMBCs to
decrease over time (Figure 2), maximizing the effectiveness of the treatment (Oyer et al., 2015).
The only problem with this method of NK proliferation is that the mechanism by which the PM
particles interact with the PBMCs is currently unknown. The current hypothesis suggests that
there may be an intermediate reaction involving macrophages or other phagocytizing cells, perhaps
even through CD4+ T lymphocytes. Understanding this pathway could lead to potentially more
expedient and efficient expansions in the future.

Experimental Objective
This study was designed to determine which PBMC cells interact with K562-mb1541BBL. This information will be used to better determine the mechanism by which the NK cells
initiate expansion. If this mechanism is determined, then a streamlining of the process may be
attempted, allowing for better NK cell purification for immunotherapy.
Alexa Fluor® 647 is a fluorophore that attaches to any surface proteins that it contacts (Life
Technologies, 2012). Additionally, when more Alexa Fluor is added, the dye gets brighter,
allowing for visualization of areas that are repeatedly contacted. The dye is viewed in the 655 nm
wavelength and is easily detectable in a flow cytometer. Therefore, to determine the way in which
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K562s interact with NK cells, we can stain K562s with Alexa Fluor® 647 (A647) and image
following days of expansion in a mixed culture. Each cell that contacts a labeled K562 cancer cell
will pick up the dye. Using a Canto Flow Cytometer, it is possible to individually count and sort
every PBMC cell in the culture. A flow cytometer takes a sample of cells and counts them
individually by firing a laser at each cell. The cells are stained with antibodies that are specific for
a certain channel, or wavelength, and therefore can be seen as distinct from the other cells.
By adding antibodies that detect specific cell types, it is also possible to sort out and individually
identify each newly labeled PBMC cell. Therefore, it is possible to determine which cells came
into contact with the A647-K562-mb15-41BBL cells by tracing the A647 wavelength. This would
show where A647 dye had been transferred from the A647-K562 cells, indicating an interaction.
Pure NK cells are CD56 +, CD3 -; NKT cells, NK cells that display T lymphocyte-like
characteristics, are CD56 +, CD3 +; and T lymphocytes are CD56 -, CD3 + (Table 1). It is
possible then, when sorting for the antibodies that correspond with these markers, to determine if
the A647 has interacted with these particular cell types. This will give us insight as to how the NK
cells and K562-mb15-41BBL cells interact. In turn, this information will allow for better future
NK cell expansion, and eventually better treatment of future cancer patients.

Table 1. The receptors of PBMC cells important to this study.
CD56 -

CD56 +

CD3 -

Other PBMCs

NK Cells

CD3 +

T cells

NK-like T Cells
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Methods and Materials
Cell Culture and PM particle production
Cultured K562-mb15-41BBL cells were harvested and centrifuged at 1000xg for 10
minutes at 4˚C. Supernatant was aspirated, and the cells washed with 100 mL DPBS containing
2mM EDTA. The cells were then centrifuged at 1000xg for 10 minutes at 4˚C. Supernatant was
aspirated, and the pellet collected, weighed, and suspended in homogenization buffer (150mM
NaCl, 2mM MgCl2, 20mM HEPES, pH 7.4) and protease inhibitor (10µg/mL Leupeptin,
10µg/mL Aprotinin, 10µM Pepstatin A, 1 mM AEBSF), where the buffer and inhibitor were
added at 10x the weight of the pellet, in mL. The contents were then transferred to the nitrogen
cavitation vessel and pressurized at 300 psi for 30 minutes at 4˚C. Homogenate was then
collected and centrifuged at 1000xg for 10 minutes at 4˚C. The supernatant was aspirated, and
then the pellet resuspended in homogenization buffer. The homogenate was then centrifuged at
100,000xg for 2 hours at 4˚C. The supernatant was aspirated, and the pellet was resuspended in
6mL of homogenization buffer in a bath sonicator at 27˚C for 25 minutes. Sixteen milliliters of
75% sucrose containing 25mM HEPES was also added while the mixture is in the sonicator.
The mixture was then transferred to tubes, and sucrose containing 25mM HEPES was added to
be 25% of the solution. The mixture was then placed in the SW41Ti rotor and centrifuged at
40,000xg for 17 hours. After centrifugation, the top 1-3 mL of supernatant was discarded. The
volume was then brought up with 1X DPBS and placed in a 70.1 rotor and centrifuged at
100,000xg for 2 hours. After, the supernatant was removed, and the pellet resuspended in 1X
DPBS, with the following equation- (Total pellet weight)/0.33= x mL DPBS. The product was
then frozen in -80˚C.
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K562-mb15-41BBL cells, for use in cellular cultures, were treated to prevent replication.
K562-mb15-41BBL cells were obtained from an already existing culture at about 1.5 million
cells/mL. Cells were centrifuged at 200xg for 5 minutes at room temperature, supernatant
removed and resuspended at a concentration of 1.0x107 cells/mL in RPMI. Mitomycin C was
added at 50 µL/mL of culture, mixed, and left to incubate for 30 minutes, mixing every 10
minutes to prevent cells from sticking to the walls of the centrifuge tube and to allow even
treatment for each cell. To rinse, RPMI was added to bring the culture to about 1.0 x106
cells/mL and centrifuged at 200xg for 5 minutes. The rinsing process was repeated twice with
RPMI, and then twice with Dulbecco’s phosphate-buffered saline (DPBS) at a pH of 7.6.
Alexa Fluor 647 Labeling
K562-mb15-41BBL cells and plasma membrane particles were labeled with Alexa Fluor
647 (A647). The following process is the same for both cells and plasma membrane particles.
The treated K562-mb15-41BBL cells or particles were split into two samples, one to be
fluorescently labeled and the other to serve as a negative control. They were centrifuged at
200xg for six minutes. The cells or particles were suspended to 1.0 x106 cells/mL (4.32 mg/mL
for plasma membranes) in PBS pH 7.6, and the A647 was added at a final concentration of
8.0x10-7 M. The cells or particles were left to incubate for one hour, resuspending every 10
minutes for better labeling. The cells were spun and washed at 200xg for 5 minutes with RPMI
containing 5% Fetal Bovine Serum (FBS) media, which functions as simulation blood, and
resuspended at 3.33x106 cells/mL in RPMI containing 5% FBS media. The cells or particles
were run on a BD Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA) using a cocktail
containing 1µL/sample CD56-PE (a fluorescent dye to label cells that have CD56 receptors, BD
Bioscience Cat# 130-090-755), 1µL/sample CD3-APC (a fluorescent dye to label cells that have
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CD3 receptors, Beckman Coulter, Cat# IM2467), and 9µL/sample DPBS containing 2mM
EDTA and 0.5% BSA, to determine if the cells were properly labeled.
The labeled and unlabeled K562-mb15-41BBL cells were cultured with PBMC cells to
create an environment where NK cells could expand. A leukopack, which is a concentrated
sample of PBMCs, was thawed at 37˚C for exactly 3 minutes, and 1mL of the leukopack was
added to 10mL RPMI containing 5% FBS, mixed, and centrifuged at 200xg for 8 minutes. The
supernatant was removed, and the cells were resuspended in 1mL of stem cell growth media
(SCGM) containing 10% FBS and IL-2 (100U/mL). A sample was taken and mixed with the
aforementioned Accuri cocktail in a 1:1 mixture and left to sit for 10 minutes in the dark. 1X
DPBS was added at 4:1 to the mixture, and 50 µL ran on a BD Accuri C6 Flow Cytometer (BD
Biosciences, San Jose, CA). Using the equations below, the amount of PBMCs, K562-mb2141BBLs, and SCGM containing 10% FBS and IL-2 to be added to the plates was determined.

𝑆𝐶𝐺𝑀 𝑀𝑒𝑑𝑖𝑎 𝑈𝑠𝑒𝑑 (𝑚𝐿) = (#𝑤𝑒𝑙𝑙𝑠) × (𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (200 µ𝐿))

(𝐼𝐿 − 2) 𝑎𝑑𝑑𝑒𝑑 (µ𝐿) = (𝑆𝐶𝐺𝑀 𝑎𝑚𝑜𝑢𝑛𝑡)/(10,000)

# 𝑜𝑓 𝑉𝑖𝑎𝑏𝑙𝑒 𝑁𝐾 𝑐𝑒𝑙𝑙𝑠 = (

(𝑃2 𝑒𝑣𝑒𝑛𝑡𝑠) × (200)
) × (%𝑁𝐾 𝑖𝑛 𝑃𝐵𝑀𝐶) × (%𝑁𝐾 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦)
1,000

The P2 events, which are events that fall within a certain gated range of cells, were calculated on
the Accuri C6 Flow Cytometer. Some NK cells are not considered viable for expansion, due to
their preexisting nature. This is why the number of viable NK cells was calculated. The NK
cells were seeded at 1:10 against feeder cells. The K562-mb15-41BBLs, PBMCs, and media
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were all pre-mixed together, the control and labeled cells separate, and then plated in a 96-well
plate in 100 µL aliquots. K562-mb15-41BBL cells by themselves were plated, as well as raw,
untreated PBMCs as controls. The plate was left to grow in the 37˚C incubator for 5 days.
The cultured cells were run through a flow cytometer to determine which cells were
expanding. Six tubes were obtained for samples, two were filled with labeled and unlabeled
cultures (PBMC + K562-mb15-41BBL), respectively, 90 µL each from the 96-well plate. The
remaining four vials were filled with pure K562-mb15-41BBL cells, 90 µL each. Versene, an
EDTA cell dissolution agent, was then added to the wells that had previously held the K562mb15-41BBL and PBMC cultures, at 50 µL/well, and stored in the 37˚C incubator for 10
minutes. After 10 minutes, the Versene was removed from the 96-well plate and added
respectively to the vials containing the sample that corresponds with the well. Two hundred
microliters of 1X DPBS was added to each of the tubes. The samples were spun at 200xg for 5
minutes, and the supernatant was aspirated. A flow cytometry cocktail was created according to
table 2.

Table 2: Flow Cytometry cocktail for determining the cells present in the PBMC + K562mb21-41BBL culture.
Flow Cytometer Cocktail

Amount

CD3-Alexa 488 (eBioscience, Cat# 53-0037-42)

2.5 µL x 1.1 x #samples

CD14 PE (BD Bioscience, Cat# 555398)

2.5 µL x 1.1 x #samples

CD19-PC7 (BD Bioscience, Cat# 349209)

2.5 µL x 1.1 x #samples

CD56-BV421 (BD Bioscience, Cat# 562751)

1.5 µL x 1.1 x #samples

Flow Buffer (DPBS containing 2mM EDTA and

50 µL x 1.1 x #samples

20
0.5%BSA)

Fifty microliters of the cocktail were added to each tube except for two samples, one containing
K562-mb15-41BBL labeled cells and K562-mb15-41BBL unlabeled cells, to which 50 µL of 1X
DPBS was added. The samples were let to sit in a 4˚C refrigerator for 30 minutes. After, 200
µL of 1X DPBS was added to each, and the samples ran on a BD FACSCANTO II flow
cytometer (BD Biosciences, San Jose CA).

Results
K562-mb15-41BBL cells and plasma membrane particles were successfully stained
In order to determine if K562-mb15-41BBL cells and plasma membrane particles were
stained so that they could be used for NK expansion, flow cytometry was conducted. Alexa 647
labeling was a success, with the labeled cells showing a bright signal at 104-105, which shows the
strength of the A647 signal, and the unlabeled cells showing a signal at 0-103 levels (Figure 3).
There is some overlap between the labeled and unlabeled cells at 103, but at significantly lower
levels than the labeled. Expression of Alexa Fluor 647 is seen exclusively in stained plasma
membrane particles, exhibiting bandwidths of 104-106, while the unstained K562-mb15-41BBL
particles have a lower emission from 0-103.

K562-mb15-41BBL cells were successfully cultured with PMBCs
In order to determine if K562-mb15-41BBL cells interacted with NK cells, PMBC cells
were cultured with K562-mb15-41BBL cells and measured using flow cytometry. The stained
K562 mb-15 cells, when cultured with PBMCs, exhibit growth patterns, expanding beyond the
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initial high concentration of T cells (Figure 4). Initial A647 levels were about 16% on the first
day of flow cytometry in NK cells, and dropped drastically to less than 1% on day 2, with a very
slow increase trending towards 1% on subsequent days (Figure 5). In NKT cells, the labeled cell
percentage is near 100% and drops to about 40%, but rises in conjunction with the unlabeled
percentage (Figure 5). Furthermore, in other cells present in the sample, such as macrophages,
there was a sharp decrease in labeled cells’ A647 percentage from 6.8% on day one to 0% in
subsequent days, while in labeled NK cells A647 percentage rose from a little over 0% to 3.75%
(Figures 6A, 6B). Unlabeled NK cells also rose from 0.8% to 3.98% A647, showing that this
may just be background noise, as the unlabeled cell cultures that should show no A647 dye are
showing similar amounts to the labeled cell cultures (Figure 4). iNK cells went from 1.9% A647
on day 1 to 5.7% A647 on day 4. Unlabeled iNK cells started at 1% A647 on day one,
progressing up to 4.4% A647 by day 4.

K562-mb15-41BBL particle membranes were successfully cultured with PBMCs
In order to determine how K562-mb15-41BBL PM particles stained a PMBC culture, the
cultures were measured using flow cytometry. Contrary to how the K562-mb15-41BBL cells
impacted the PMBCs, the plasma membrane particles selectively expanded NK cells and T cells
without expanding either NKT or iNK cells, as only NK and T cells showed labeling, with NKT
and iNK showing no labeling (Figure 7). NK cells started off with rapid expansion from days 12, rising to 60% labeled. By day 7, NK cells had reached their most labeled at 90%, before
declining to 60% on day 9. T cells also were labeled by the K562-mb15-41BBL cells, but at a
lesser rate than NK cells, only overtaking them by day 9, at 75%.
Discussion
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Cancer is a disease through which the most common methods of treatment involve
poisoning, irradiating, or cutting the body, and all suffer from significant side effects (Corrie,
2008; Malhotra and Perry, 2003). An upcoming form of treatment, immunotherapy, has seen
progress in recent decades, but is not quite ready to be applied in the clinical setting. Attempts
have been made to utilize T-lymphocytes and various cytokines in hopes of causing an expanded
and more targeted immune system, but there have been few successful results (Denman et al.,
2012; Guermonprez et al., 2002; Singh et al., 2011; Vivier et al., 2012). NK cells, by
comparison, are able to remove cancer cells effectively and safely (Bachanova and Miller, 2014;
Miller, 2013). Activation of these NK cells by cancer cells with membrane-bound cytokines
eliminates the toxicity encountered by injecting pure IL-2 cytokines and allows for an initial
expansion and specificity to cancer cells before injection into the patient, creating NK cells that
will seek only cancer cells, avoiding other immune system problems (Childs and Berg, 2013; Ni
et al., 2012; Sim and Radvanyi, 2014). These cultures of K562-mb15-41BBL cells and PBMCs,
by which the NK cells are expanded, cannot be directly injected into a patient, however, as this
can potentially give them the K562-mb15-41BBL strain of cancer, even if the K562-mb1541BBLs are rendered helpless. Therefore, plasma membrane particles of the K562-mb1541BBLs are used to culture the NKs, as part of the cell membrane cannot transmit the cancer.
The results of this study help to identify the specific pathways by which the K562-mb15-41BBLs
interact with all the cells in a PBMC sample. By learning this pathway, the proliferation of the
NKs can potentially be increased, and the process streamlined.
By knowing which receptors are present on each type of immune cell, it is possible to
sort the cells individually through a flow cytometer and determine which of the cells
accumulated the Alexa Fluor 647 conjugate dye from the labeled K562-mb15-41BBL cells or
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particles. The dye transfers from the labeled cells to unlabeled cells only when the proteins
present on the surfaces of each cell interact with each other (Technologies, 2007). Cells that are
CD14+, regardless of other receptors, did not pick up any of the A647 dye (Figure 6). CD14 is
used as marker for monocytes and macrophages, as it is present on these cells to identify Gramnegative bacteria (Jersmann, 2005). Therefore, the labeled K562-mb15-41BBL cells do not
interact with macrophages or monocytes, an anticipated result considering the receptors that have
been grafted onto the K562-mb15-41BBL cancer cells (Oyer et al., 2015). The K562-mb1541BBLs have membrane-bound IL-15, a cytokine that has been shown to proliferate and mature
NK cells (Parrish-Novak et al., 2000). This cytokine attracts the NK cells, giving the K562mb15-41BBLs a lower affinity for the macrophages, which are attracted to cancerous cells
(Belgiovine et al., 2016; Hanahan and Weinberg, 2011). As the interaction between the labeled
K562-mb15-41BBL cells and the cells presenting CD14 is extremely low, it can be determined
that macrophages are not part of the specification and maturation of NK cells.
CD56-, CD3- cells may be a form of NK cell called immature NK cells, known also as
iNK cells (Yoon et al., 2015). Although macrophages are not part of the specification and
maturation of NK cells, CD56-, CD3- iNK cells might be required for the process. The A647
dye was transferred at about a three-fold increase to these cells (Figure 6). It is important to note
that the background noise in the unlabeled cells also increased the labeled samples, indicating a
possible non-result. The transfer of dye to iNK cells is an unusual interaction, as cells without
CD56 or CD3 are typically not identified with either NK cells or T cells (Miller, 2015; Miller et
al., 2005). These iNK cells cannot make up the entirety of the CD56-, CD3- population, as many
cells exist in a PBMC sample that do not have the receptors CD56 or CD3. If some of these iNK
cells are affected by the labeled K562-mb15-41BBL cells, however, then they might play a role
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in the specification of the CD56+ NK cells. It is possible that these cells experience maturation
and specification while in culture with the K562-mb15-41BBL cells, but as the flow cytometry
was only carried out for a four-day period, this is still currently unknown.
Another subset of NK cells are prominent within PBMC samples, CD56+, CD3+ NKT
cells. NKT cells activate in response to cancer cells via recognition of a CD1d receptor on the
cell. NKTs also specify NK cells themselves to the cancer in a method similar to that employed
by helper and cytotoxic T cells (Vivier et al., 2012). These CD56+, CD3+ NKT cells showed
significant accumulation of the A647 dye, more than any other cell type in the PBMCs (Figure
5). The background of the NKT and the unlabeled K562-mb15-41BBLs cultured with PBMCs
also increased slightly, showing that the actual uptake of A647 might be smaller than implicated.
As these NKT cells appear to be picking up the most A647 by a significant margin, this could be
the first step in the proliferation and maturation of regular NK cells. IL-15, in addition to being
specific for NK cells, is specific for NKT cells, allowing for the NKT cells in suspension with
the K562-mb15-41BBLs to bind. NKT cells express 4-1BBL on their cell surface as well, which
is necessary for the NK cells to track and destroy cancer cells, as the NKs bind to the 4-1BBL
receptor to specify for cancer destruction (Alderson and Sondel, 2011; Cole et al., 2014). The
K562-mb15-41BBLs already possess 4-1BBL on their surface so to see significant amounts of
NKT cells interacting with them may suggest that there is another mechanism at play directing
NK and NKT cells. If there were no other such mechanism, one would expect at least equal
numbers of NK and NKT absorbing the A647 during initial days. It is also possible that the IL-2
put into the solution caused the proliferation of NKTs alongside NKs during the initial days.
Pure NK cells, CD56+, CD3- received little A647 in comparison with NKTs (Figure
4A,B). This was perhaps the most surprising result of the study, as the K562-mb15-41BBL cells
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significantly expand pure NKs, considering the IL-15 and 4-1BBL membrane-bound cytokines
were put there specifically to target these cells (Denman et al., 2012; Oyer et al., 2015; ParrishNovak et al., 2000). The IL-2 placed into the system is known to expand T cells as well as
NKTs, but at the quantities added, it should have expanded the regular NK cells as well. The
rising of the background in CD14-, CD56+, CD3- cells suggests that there was very little, if any,
labeling transferred. In previous trials, it is noted that regular expansion of the NK cells is not
consistent until after the fourth day of expansion, the final day of which the cells were imaged
(Oyer et al., 2015). Even with this being the case, at least partial expansion of NK cells was
expected. Either the proposed mechanism of direct contact between K562-mb15-41BBLs and
NKs is correct and the contact does not happen until after four days, or another method occurs
between the two cells that does not require contact. The activation of NK cells by NKT cells
might be viable, as the NKT cells would make contact with the K562-mb15-41BBL cells and
then contact the NK cells via another receptor, therefore not spreading the conjugation dye
(Figure 8).
An interesting point of contradiction resides in the data received from the plasma
membrane (PM) particles. The PM particles labeled NK cells and T cells with startling
efficiency (Figure 7). This discrepancy as contrasted to the labeling transferred from whole cells
might be a result of the concentration and availability of PM particles. As the PM particles are
made of extruded K562-mb15-41BBL cells, they are significantly smaller than the K562-mb1541BBLs, allowing them to more effectively penetrate the collection of PMBC cells. This would
allow them to reach more NK cells, which are initially present at lower numbers than other
PMBC cells (Oyer et al., 2015). As the PM particles were able to reach the NK cells more
efficiently, their membrane-bound IL-15 and 4-1BBL receptors could interact with the NK cells
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as intended, as opposed to through the NKT cells. T cells also picked up the A647 dye due to
their own interactions with CD3 (Parrish-Novak et al., 2000). More research must be done to
determine why T cells would accumulate more A647 dye later in the expansion process.
Additionally, more research must be conducted to determine why A647 labeled PM particles are
superior at labeling NK cells in comparison with K562-mb15-41BBL whole cells.
This experiment sought to determine which PBMC cells are affected by K562-mb1541BBL cells using A647 dye, in an effort to better refine the NK cell maturation process. High
interaction between K562-mb15-41BBL and NKT cells were reported, as well as significant
interaction between K562-mb15-41BBL and iNK cells, but not with pure NK cells. A different
method of NK specification may be the cause of such low NK cell labeling. Future testing
methods are currently being considered for how NK cells could specify to the K562-mb1541BBLs. For example, the role of microRNAs in specifying ligands present on NK cells and
cytotoxic T cells is considered an alternative route of NK cancer specificity (Jasinski-Bergner et
al., 2014; Presnell et al., 2015). If these microRNAs are playing a role in the specification of NK
when introduced to K562-mb15-41BBLs, it could account for the lack of direct physical contact
between NK and K562-mb15-41BBL. Another possible method of NK specification comes
through exosomes, which are produced by both dendritic cells and the cancer cells (Gehrmann et
al., 2014; Reiners et al., 2014). These exosomes may be triggering the NKs to expand, and as
they come from within the cell, may lack the A647 dye. Understanding this interaction will
allow for a better future immunotherapy, and eventually lead to successful treatment of cancers
in a way that does not harm the body as much as surgery, radiation, or chemotherapy.
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Figures
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Appendix B: Glossary
ADCC (antibody dependent cell-mediated cytotoxicity): Administration of activating cytokines
such as IL-12, IL-2, and IL-21, as well as various antibodies like disaloganglioside to alter the NK
Fc receptor CD16, preventing cancer cells from proliferation.
Alexa Fluor 647: A fluorophore that attaches to the surface proteins of cells. Transfers when cells
conjugate with each other.
Auto-Expansion: The expansion of one’s own NK cells.
B lymphocyte: white blood cell that expresses B-cell receptors on their membranes and originate
and mature in bone marrow. Uses antibodies such as IgM, IgG, and IgA to overwhelm antigens.
Proliferate into short-term plasmoblasts, which remove the immediate antigen problem by
secreting large amounts of antibodies to overwhelm the pathogen, and memory B lymphocytes,
which remain in the body in case of a secondary infection by the same pathogen.
CAR-T: Chimeric antigen receptor T lymphocyte based therapy. Able to recognize cancerous
cells with MHC down-regulation.
CD3: Receptor present on all T lymphocytes
CD4: Receptor on T lymphocytes that release IL-2 to cause the death of infected cells
CD8: Receptor on T lymphocytes that directly cause apoptosis
CD16: Receptor that is altered in ADCC-mediated therapies
CD56: Receptor on NK cells
CD137/4-1BBL: Signaling domain for tumor necrosis factor. Important for CAR-T and NK
expansion. trans-membrane cytokine that interacts with T lymphocytes, specifically CD8+
lymphocytes
Helper T Cell: Stimulates the production of B lymphocytes via cytokines.
IFN- γ: Cytokine that stimulates the activation of B lymphocytes, T lymphocytes, and other
macrophages.
IL-2: Cytokine that stimulates the activation of B lymphocytes, T lymphocytes, and other
macrophages, specifically NK cells.
IL-12/15/18: Interleukins found to specify NK cells for cancer destruction. IL-15 is of particular
note to this study, forming the mb-15 bound part of K562-mb15-41BBL cells.
IL-15: A chemokine essential for the expansion of NK cells.
iNK cells: Immature NK cells, found in PBMC samples. Perhaps useful for specification of NK
cells.
K562: Immortalized myelogenous leukemia cells, specifically used for NK expansion.
K562-mb15-41BBL: Immortalized myelogenous leukemia cells, modified to include membranous
IL-15 and CD137/4-1BBL. Used for NK cell expansion.
MHC (major histocompatibility complex) Class I: Utilized on the surface of the body’s own
cells, MHC Class I molecules present antigens from invasive pathogens for the adaptive immune
system to recognize and act on.
MHC (major histocompatibility complex) Class II: Found on dendritic cells, and other PBMC
cells. Used to activate other adaptive immune cells.
Mitomycin C: DNA cross-linker, used to render K562 cells incapable of mitosis.
NK (natural killer) Cells: Considered part of both the innate and adaptive immune system, do not
attack invasive pathogens. They attack infected or abnormally growing host cells, inducing
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apoptosis in the target cell, including cancer cells. They identify these cells by recognizing low
concentrations of MHC class I molecules, a trait of cancerous cells.
PMBC: Peripheral mononuclear blood cell. Contains all white blood cells, purified from raw
blood from donors.
T lymphocyte: white blood cell that originates in the thymus and is part of the adaptive immune
system. There are two main types, cytotoxic T cells and helper T cells. Cytotoxic T cells are
CD8+ and recognize MHC class I antigen presentation, while helper T cells (CD4+) utilize IL-2
and other cytokines to destroy MHC class II presenting cells.
TIL (Tumor infiltrating lymphocytes): Found in cancer cells, used for some T cell
immunotherapies.
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